EVP at Dianthus (DNTH) awarded 150,000 stock options over 4 years

Rhea-AI Filing Summary

Dianthus Therapeutics executive Simrat Randhawa, EVP and Head of R&D, reported a grant of stock options. On February 3, 2026, Randhawa received 150,000 stock options with an exercise price of $52.46 per share, all held directly.

The options relate to Dianthus common stock and begin vesting from January 1, 2026. They vest in equal monthly installments over four years, conditioned on Randhawa’s continued service with the company on each vesting date, and expire on February 3, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Randhawa Simrat

Role EVP, Head of R&D

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Randhawa Simrat

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$52.46	02/03/2026		A		150,000		(1)	02/03/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Simrat Randhawa	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Dianthus Therapeutics (DNTH) Form 4 filing report?

The Form 4 reported a stock option grant to executive Simrat Randhawa. On February 3, 2026, Randhawa received 150,000 stock options for Dianthus common stock, documenting a new equity-based compensation award rather than a market purchase or sale of existing shares.

How many Dianthus (DNTH) stock options did Simrat Randhawa receive?

Simrat Randhawa received 150,000 stock options. These options give the right to buy 150,000 shares of Dianthus common stock, are held directly, and represent Randhawa’s derivative beneficial ownership following this reported transaction on February 3, 2026.

What is the exercise price of Simrat Randhawa’s Dianthus stock options?

The options have an exercise price of $52.46 per share. This means Randhawa can purchase Dianthus common stock at $52.46 for each of the 150,000 underlying shares, subject to vesting conditions and the option term ending on February 3, 2036.

When do Simrat Randhawa’s Dianthus (DNTH) stock options vest?

The options vest in equal monthly installments over four years. Vesting starts after January 1, 2026, and continues monthly, provided Randhawa remains in service with Dianthus on each vesting date, gradually increasing the number of exercisable options over time.

What role does Simrat Randhawa hold at Dianthus Therapeutics (DNTH)?

Simrat Randhawa serves as EVP, Head of R&D at Dianthus. The Form 4 identifies Randhawa as an officer, not a director or 10% owner, and reports this stock option grant as part of compensation tied to continued service with the company.

Is the reported Dianthus (DNTH) transaction a direct or indirect holding for Randhawa?

The stock options are reported as a direct holding. The Form 4 lists the ownership form as "D" for direct, with no footnote indicating another entity or trust, so the 150,000 options are attributed directly to Simrat Randhawa.